A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
Special Drug Use Investigation (Survey) of Yervoy and Opdivo Combination Therapy in Patients With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Tokyo
-
Shinjuku-ku, Tokyo, Japan, 162-0822
- Local Institution
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Initiated treatment with Yervoy and Opdivo in combination for the first time in accordance with the Japanese package insert
Exclusion Criteria:
- Received combination therapy with Yervoy and Opdivo for indications other than Malignant Pleural Mesothelioma (MPM).
- Received the Yervoy and Opdivo combination for MPM, but for an indication that is outside of the Japanese package insert.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Cohort 1
Participants with unresectable advanced/recurrent malignant pleural mesothelioma (MPM)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of Adverse Events (AEs)
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Time to onset of serious adverse events (SAEs)
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Time to onset of AEs
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Time to resolution of AEs
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Time to resolution of SAEs
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Incidence of physician seriousness assessment measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade - Non-serious AE
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Incidence of physician seriousness assessment measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade - SAE
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Incidence of AEs leading to interruption of treatment
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Incidence of SAEs leading to interruption of treatment
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Incidence of AEs leading to treatment discontinuation
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Incidence of SAEs leading to treatment discontinuation
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Outcome of reported AEs
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Outcome of reported SAEs
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Number of participants with Yervoy and Opdivo treatment related adverse events as assessed by physician causality
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Number of participants with Yervoy and Opdivo treatment unrelated adverse events as assessed by physician causality
Time Frame: Up to 6 Months
|
Up to 6 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CA209-6AF
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.